Merck, Eli Lilly, Pfizer, and Bristol Myers Squibb agreed to stop initiating new trials at Chinese military hospitals and within the Xinjiang region following congressional inquiries. AbbVie also committed to avoiding facilities tied to the People’s Liberation Army, but it declined to halt trials in Xinjiang to continue treating critical oncology patients. Meanwhile, U.S. health developments face regulatory friction as telehealth companies expand unapproved peptide offerings and a major scientific integrity report faces citation delays.
Key points
Heightened congressional oversight is driving American pharmaceutical giants to sever sen…: Heightened congressional oversight is driving American pharmaceutical giants to sever sensitive clinical research ties within China.
Telehealth platforms are marketing unapproved compounded peptides to consumers following…: Telehealth platforms are marketing unapproved compounded peptides to consumers following controversial guidance from agency leadership.
A prominent national report on scientific misconduct was paradoxically sidelined by basic…: A prominent national report on scientific misconduct was paradoxically sidelined by basic reference and citation errors.
Sources checked by our analysis pipeline: 1
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning, everyone. Are you a fan of “Grand Theft Auto”? Will your boss not give you the day off to play the video game you’ve been waiting 13 years for? Don’t worry, DJ Khaled and Dr. Xbox have you covered. Just click here and fill out the form. You’ll have a diagnosis and doctor’s note for Vitamin G deficiency faster than a telehealth company can prescribe you a peptide.
Which, speaking of …
Peptides go mainstream
Unapproved and off-label peptide drugs have long been popular with bodybuilders looking for an edge, but they could soon become a mass market health product, thanks to new initiatives from two popular telehealth companies.
Hims & Hers unveiled Thursday its Peptides+ program, offering two peptides alongside several compounded medications popular among peptide users. Noom announced its own offerings this week as well. This follows a decision by FDA leaders to — despite the concerns of staff scientists – allow compounders to produce six peptides…
Major global drugmakers have achieved substantial time savings by expanding artificial intelligence applications into core scientific processes rather than limiting them to administrative tasks. At the same time, top pharmaceutical firms are altering their clinical footprints abroad in response to sustained pressure from federal lawmakers. These parallel shifts highlight growing operational transformations across molecular discovery pipelines and international research strategies.
Federal health authorities are actively probing a gastrointestinal sickness aboard the Caribbean Princess after nearly 150 individuals experienced vomiting and diarrhea. While suspected to be norovirus, laboratory tests are currently underway to identify the precise pathogen responsible for the infections. The vessel continues along its planned international route as the cruise line imposes sanitation and isolation protocols.
The emerging data offer an initial look at how Alterome's experimental therapy performs against several major oncological targets. Developers are evaluating the compound specifically across difficult-to-treat malignancies, including pancreatic, lung, and colorectal cancers. These preliminary findings mark a pivotal step in assessing the candidate's viability in the competitive KRAS inhibitor pipeline.